OBJECTIVE: To compare the effect of moxifloxacin as a positive control in a single ascending dose (SAD) study with that in a thorough QT (TQT) study. METHODS:Moxifloxacin was used as a positive control in a SAD study and a TQT study during the evaluation of the QT liability of a new drug. The SAD study had enrolled 24 males and the TQT study 25 males. Both studies intensively monitored electrocardiograms (ECGs) and pharmacokinetic sampling. Effect of moxifloxacin on QTc interval was analysed in each study by intersection union test (IUT) and by exposure-response (ER) analysis and the results compared. Cost-effectiveness of this approach was computed. RESULTS: Analysis by IUT revealed that the maximum mean (90 % confidence interval (CI)) placebo-corrected change from baseline (ΔΔQTcF) in the SAD study and the TQT study were remarkably similar (10.7 (6.5; 14.9) ms vs. 9.09 (6.20; 11.98) ms, respectively). In both studies, assay sensitivity was established by the 90 % lower bound exceeding 5 ms. ER analysis revealed the slopes in both studies to be significantly different from zero and comparable. Bootstrap-predicted effects of moxifloxacin at geometric mean concentrations of ~3000 ng/mL were 8.19 (90 % CI 5.86; 10.7) ms in the SAD study and 7.33 (90 % CI 5.69; 9.70) ms in the TQT study. CONCLUSION:Moxifloxacin can be integrated effectively in a SAD study to establish assay sensitivity, and a TQT study may be replaced by a SAD study which has the required assay sensitivity. Further experience is warranted to verify this conclusion.
RCT Entities:
OBJECTIVE: To compare the effect of moxifloxacin as a positive control in a single ascending dose (SAD) study with that in a thorough QT (TQT) study. METHODS:Moxifloxacin was used as a positive control in a SAD study and a TQT study during the evaluation of the QT liability of a new drug. The SAD study had enrolled 24 males and the TQT study 25 males. Both studies intensively monitored electrocardiograms (ECGs) and pharmacokinetic sampling. Effect of moxifloxacin on QTc interval was analysed in each study by intersection union test (IUT) and by exposure-response (ER) analysis and the results compared. Cost-effectiveness of this approach was computed. RESULTS: Analysis by IUT revealed that the maximum mean (90 % confidence interval (CI)) placebo-corrected change from baseline (ΔΔQTcF) in the SAD study and the TQT study were remarkably similar (10.7 (6.5; 14.9) ms vs. 9.09 (6.20; 11.98) ms, respectively). In both studies, assay sensitivity was established by the 90 % lower bound exceeding 5 ms. ER analysis revealed the slopes in both studies to be significantly different from zero and comparable. Bootstrap-predicted effects of moxifloxacin at geometric mean concentrations of ~3000 ng/mL were 8.19 (90 % CI 5.86; 10.7) ms in the SAD study and 7.33 (90 % CI 5.69; 9.70) ms in the TQT study. CONCLUSION:Moxifloxacin can be integrated effectively in a SAD study to establish assay sensitivity, and a TQT study may be replaced by a SAD study which has the required assay sensitivity. Further experience is warranted to verify this conclusion.
Entities:
Keywords:
Assay sensitivity; Exposure-response analysis; ICH E14; Intersection union test; Single ascending dose study; Thorough QT study
Authors: B Darpo; C Benson; C Dota; G Ferber; C Garnett; C L Green; V Jarugula; L Johannesen; J Keirns; K Krudys; J Liu; C Ortemann-Renon; S Riley; N Sarapa; B Smith; R R Stoltz; M Zhou; N Stockbridge Journal: Clin Pharmacol Ther Date: 2015-04 Impact factor: 6.875
Authors: D M Bloomfield; J T Kost; K Ghosh; D Hreniuk; L A Hickey; M J Guitierrez; K Gottesdiener; J A Wagner Journal: Clin Pharmacol Ther Date: 2008-10 Impact factor: 6.875
Authors: Fred Poordad; Gillian Zeldin; Stuart I Harris; June Ke; Limin Xu; Douglas Mayers; Xiao-Jian Zhou Journal: J Clin Pharmacol Date: 2009-10-15 Impact factor: 3.126
Authors: Vipul K Gupta; Gary Maier; Paul Eckburg; Lisa Morelli; Yang Lei; Akash Jain; Erika Manyak; David Melnick Journal: Antimicrob Agents Chemother Date: 2021-06-17 Impact factor: 5.191
Authors: Zancong Shen; Michael Gillen; Kathy Tieu; Mai Nguyen; Erin Harmon; David M Wilson; Bradley Kerr; Caroline A Lee Journal: Drug Des Devel Ther Date: 2016-10-27 Impact factor: 4.162
Authors: Jörg Täubel; Ulrike Lorch; Simon Coates; Sara Fernandes; Paul Foley; Georg Ferber; Jean-Pierre Gotteland; Oliver Pohl Journal: Clin Pharmacol Drug Dev Date: 2018-02-28
Authors: Mojgan Kavoosi; Terry E O'Reilly; Mehran Kavoosi; Peng Chai; Caroline Engel; Walter Korz; Christopher C Gallen; Robert M Lester Journal: Toxins (Basel) Date: 2020-08-09 Impact factor: 4.546